Provided by Tiger Fintech (Singapore) Pte. Ltd.

Corvus Pharmaceuticals

8.17
+0.26003.29%
Volume:1.05M
Turnover:8.52M
Market Cap:610.15M
PE:-14.62
High:8.27
Open:7.92
Low:7.78
Close:7.91
52wk High:10.00
52wk Low:2.54
Shares:74.68M
Float Shares:57.36M
Volume Ratio:0.79
T/O Rate:1.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5587
EPS(LYR):-1.0214
ROE:-35.82%
ROA:-34.87%
PB:8.50
PE(LYR):-8.00

Loading ...

Corvus Pharmaceuticals Reports Positive Q3 Earnings Call

TIPRANKS
·
Nov 06

Stock Track | Corvus Pharmaceuticals Plummets 5.63% Following Q3 Net Loss Report

Stock Track
·
Nov 05

Corvus Pharmaceuticals Shares Down 2.1% After Co Reports Q3 Net Loss

THOMSON REUTERS
·
Nov 05

H.C. Wainwright Sticks to Its Buy Rating for Corvus Pharmaceuticals (CRVS)

TIPRANKS
·
Nov 05

Corvus Pharmaceuticals reports third quarter 2025 financial results

Reuters
·
Nov 05

BRIEF-Corvus Pharmaceuticals Q3 EPS USD -0.12

Reuters
·
Nov 05

Corvus Pharma Q3 EPS $(0.12) Beats $(0.14) Estimate

Benzinga
·
Nov 05

Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition

GlobeNewswire
·
Nov 03

We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth

Simply Wall St.
·
Nov 01

Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

GlobeNewswire
·
Oct 31

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025

GlobeNewswire
·
Oct 29

Corvus Pharmaceuticals’ Phase 3 Study on Soquelitinib: A Potential Game-Changer in Lymphoma Treatment

TIPRANKS
·
Oct 28

Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025

GlobeNewswire
·
Oct 17

Corvus Pharmaceuticals Initiated at Overweight by Barclays

Dow Jones
·
Oct 13

Corvus Pharmaceuticals initiated with an Overweight at Barclays

TIPRANKS
·
Oct 13

Corvus Pharmaceuticals (CRVS) Has a New Rating from Barclays

TIPRANKS
·
Oct 13

Corvus Pharmaceuticals Files Initial Beneficial Ownership Statement for Director David Scott Moore

Reuters
·
Oct 07

Press Release: Corvus Pharmaceuticals Appoints David Moore to Board of Directors

Dow Jones
·
Oct 03

While institutions invested in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) benefited from last week's 12% gain, individual investors stood to gain the most

Simply Wall St.
·
Sep 25

Corvus Pharmaceuticals : Oppenheimer Cuts Target Price to $15 From $17

THOMSON REUTERS
·
Aug 08